Mashup Score: 1
American College of CardiologyIn patients without an indication for long-term anticoagulation after successful TAVR, the incidence of subclinical leaflet thrombosis (SLT) was numerically lower – but not statistically significant – with edoxaban than with dual antiplatelet therapy (DAPT), according to findings from the ADAPT-TAVR trial presented April 4 at ACC.22 and published in Circulation. The effects on new...
-
123456
More coverage:
#ACC22
Read the full article here